Iradimed (IRMD) Price to Sales (2014 - 2026)

Iradimed (IRMD) has reported Price to Sales for 13 consecutive years, with 59.7 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Price to Sales rose 60.22% year-over-year to 59.7 in Q2 2026; TTM through Jun 2026 was 14.15, a 44.47% increase from a year earlier, with the FY2025 full-year figure at 14.84, up 55.44% from the prior year.
• Price to Sales was 59.7 for Q2 2026 at Iradimed, up from 55.98 in the prior quarter.
• Over five years, Price to Sales peaked at 59.7 in Q2 2026 and troughed at 23.96 in Q4 2022.
• A 5-year average of 38.18 and a median of 34.6 in 2023 frame the typical range for Price to Sales.
• Across the five-year window, Price to Sales plunged 50.91% in 2022 and jumped 63.69% in 2026, its largest moves.
• Over 5 years, Price to Sales stood at 23.96 in 2022, then jumped by 43.7% to 34.44 in 2023, then rose by 4.7% to 36.05 in 2024, then soared by 51.98% to 54.8 in 2025, then gained by 8.96% to 59.7 in 2026.
• The last three Price to Sales figures came in at 59.7 (Q2 2026), 55.98 (Q1 2026), and 54.8 (Q4 2025), per Business Quant data.